About John Beaver
John Beaver is CEO of Sentonix, a Massachusetts biotech developing small-molecule drugs for Parkinson's, Alzheimer's and other neurodegenerative diseases. In January 2026 Sentonix signed a global strategic collaboration with Mabwell, a drug maker listed in Shanghai. Since 2026 he has also been a director of Defence Therapeutics.
He was vice president and head of global biomarker discovery and development at Biogen. Before that he led translational imaging at AbbVie, was a senior imaging scientist at GlaxoSmithKline and was director of imaging at Maccine.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name John Beaver in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people John Beaver works with at each company, as listed on that company's latest Form D.
